GOSSELIES, BELGIUM – March 26, 2019 – MaSTherCell S.A. a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated Contract Development and Manufacturing Organization (CDMO) announces today that it has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed…Continue reading "MaSTherCell SA Announces Creation of a new Commercial Manufacturing Facility for Cell & Gene Therapies"
GREENWICH, CT and HOUSTON, TX – January 25, 2019 – Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry, announces today that its portfolio company and strategic partner MaSTherCell Global, Inc. (“MaSTherCell Global”) achieved its first financial milestone targets and as a result Great Point has funded $6.6…Continue reading "Great Point Partners-Backed Strategic Partner MaSTherCell Global Announces Achievement of First Milestone Funding and Expansion with New Facility in Houston, Texas"
GOSSELIES, BELGIUM – November 30, 2018 – MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) launched a new production wing of 600 m² at its Belgium site in the presence of the Public Health and Social Affairs Minister, Maggie De Block and…Continue reading "MaSTherCell expands production by doubling its capacity"
SAN CARLOS, CA and GOSSELIES, BELGIUM – October 18, 2018 – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announced…Continue reading "Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe"
Seoul, Korea and Gosselies, Belgium, October 1, 2018 – Kangstem Biotech, a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, today announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD. MaSTherCell, a subsidiary of Orgenesis Inc. (NASDAQ:ORGS) through Masthercell…Continue reading "Kangstem Biotech selects MaSTherCell for GMP manufacturing of FURESTEM-AD© in Europe"
Gosselies, Belgium – July 2, 2018. MaSTherCell, a leading Cell therapy Contract and Manufacturing Organization (CDMO), announced today a new strategic step in its corporate development. MaSTherCell Global – a gathering of MaSTherCell (Belgium), Atvio Biotech Ltd., an Israel-based CDMO partner, and Curecell Co. Ltd., a Korea-based CDMO partner – will beneficiate from a USD…Continue reading "MaSTherCell announces planned investment for MaSTherCell Global of up to $25 Million to develop its global services through a strategic partnership between Orgenesis and Great Point Partners"